On this Would possibly 4, 2020 image supplied by the Faculty of Maryland College of Medication, the first affected individual enrolled in Pfizer’s COVID-19 coronavirus vaccine scientific trial on the Faculty of Maryland College of Medication in Baltimore, receives an injection.
Faculty of Maryland College of Medication | AP
Pfizer may need outcomes from its late-stage coronavirus vaccine trial as early as October, CEO Albert Bourla acknowledged Thursday.
The pharmaceutical agency has already enrolled 23,000 volunteers throughout the half three trial that began in late July, Bourla acknowledged all through a Q&A with the Worldwide Federation of Pharmaceutical Producers & Associations, a commerce group. It hopes to enroll on the very least 30,000 people, he acknowledged.
“We anticipate by the highest of October, we should always all the time have adequate … to say whether or not or not the product works or not,” he acknowledged.
This is usually a rising story. Please look at once more for updates.
